Detalhe da pesquisa
1.
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
Haematologica
; 106(6): 1559-1568, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32467145
2.
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
Hematol Oncol
; 39(5): 680-686, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402088
3.
Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.
Leukemia
; 37(2): 478-487, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36526735
4.
Systematic benchmarking of single-cell ATAC-sequencing protocols.
Nat Biotechnol
; 2023 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537502
5.
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
Leukemia
; 36(7): 1781-1793, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35590033
6.
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.
Leuk Lymphoma
; 64(2): 483-486, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533589
7.
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
Leuk Lymphoma
; 63(6): 1512-1514, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133227
8.
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia.
Leuk Lymphoma
; 62(3): 755-757, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150814